Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study Comparing Investigational Drug HBI-8000 Combined With Nivolumab vs. Nivolumab in Patients With Advanced Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04674683
Recruitment Status : Recruiting
First Posted : December 19, 2020
Last Update Posted : January 12, 2021
Sponsor:
Information provided by (Responsible Party):
HUYA Bioscience International

Brief Summary:
This is a phase 3 study to compare the efficacy and safety of HBI-8000 or Placebo combined with nivolumab on patients with unresectable or metastatic melanoma and eligible patients who are not adolescents or patients with new, progressive brain metastasis will be stratified by PD-L1 expression and LDH level.

Condition or disease Intervention/treatment Phase
Unresectable or Metastatic Melanoma Progressive Brain Metastasis Drug: HBI-8000 in combination with nivolumab Drug: Placebo in combination with nivolumab Phase 3

Detailed Description:

This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 study of HBI-8000 or Placebo combined with nivolumab. Randomization of eligible patients who are not adolescents or patients with new, progressive brain metastasis will be stratified by PD-L1 expression (positive, ≥5% expression level versus negative, <5% expression level) and LDH (normal versus elevated). Adolescents and patients with new, progressive brain metastasis will be randomized in a separate stratum.

All Eligible patients will be randomized within the appropriate stratum at a 1:1 ratio to the Test arm or the Control arm. Study treatment will be initiated within 3 days of randomization.

A treatment cycle consists of 28 days. Patients will be treated with one of the following:

Test arm: HBI-8000 30 mg oral BIW + nivolumab 480 mg IV Q4W Control arm: Placebo oral BIW + nivolumab 480 mg IV Q4W The Study Treatment of HBI-8000 or Placebo is administered at 30 mg orally twice a week (BIW), approximately 30 minutes after the first standard meal of the day.

The Study Treatment (HBI-8000 or Placebo) will be administered twice a week on the following days of every 28-day cycle:

  • CxW1: Days 1, 4
  • CxW2: Days 8, 11
  • CxW3: Days 15, 18
  • CxW4: Days 22, 25 Study treatment must commence within 3 days after randomization and continue up to 2 years or until disease progression (confirmed), unacceptable toxicity or patient withdrawal of consent.

In addition to Study Treatment, nivolumab is administered at 480 mg IV Q4W as an intravenous infusion over 30 minutes in accordance with the manufacturer regional product information insert and the institution's prescribing practice. For adolescents weighing < 40 kg, nivolumab will be dosed at 6 mg/kg every 4 weeks.

Nivolumab will be administered on Day 1 of each cycle. Note: Adults with new, progressive brain metastasis, or adolescents with or without new progressive brain metastasis will be randomized as a separate cohort to ensure balanced randomization to the two arms.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 480 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: This is a placebo-controlled Phase 3 study of HBI-8000 or Placebo combined with nivolumab. Eligible patients who are not adolescents or patients with new, progressive brain metastasis will be stratified by PD-L1 expression and LDH (normal versus elevated).
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: This is a randomized, double-blind study. All Eligible patients will be randomized within the appropriate stratum at a 1:1 ratio to the Test arm or the Control arm.
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind Phase 3 Study of HBI-8000 Combined With Nivolumab Versus Placebo With Nivolumab in Patients With Unresectable or Metastatic Melanoma Not Previously Treated With PD-1 or PD-L1 Inhibitors
Estimated Study Start Date : January 7, 2021
Estimated Primary Completion Date : December 2024
Estimated Study Completion Date : October 2025

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Melanoma
MedlinePlus related topics: Melanoma
Drug Information available for: Nivolumab

Arm Intervention/treatment
Experimental: Test Arm
HBI-8000 30 mg oral BIW + nivolumab 480 mg IV Q4W
Drug: HBI-8000 in combination with nivolumab
Patients will take 30 mg of HBI-8000 orally approximately 30 minutes after the first full meal of the day, beginning on Day 1 and continue every 3 to 4 days on the BIW schedule. On Day 1 of each cycle nivolumab 480 mg IV will be administered by intravenous infusion in accordance with OPDIVO® manufacturer regional product information insert and the institution's prescribing practice. In adolescent patients with body weight < 40 kg, nivolumab will be dosed at 6 mg/kg Q4W.
Other Name: For HBI-8000: tudicdinostat; For nivolumab: OPDIVO®

Placebo Comparator: Control Arm
Placebo oral BIW + nivolumab 480 mg IV Q4W
Drug: Placebo in combination with nivolumab
Patients will take 30 mg of Placebo orally approximately 30 minutes after the first full meal of the day, beginning on Day 1 and continue every 3 to 4 days on the BIW schedule. On Day 1 of each cycle nivolumab 480 mg IV will be administered by intravenous infusion in accordance with OPDIVO® manufacturer regional product information insert and the institution's prescribing practice. In adolescent patients with body weight < 40 kg, nivolumab will be dosed at 6 mg/kg Q4W.
Other Name: For nivolumab: OPDIVO®




Primary Outcome Measures :
  1. Primary Outcome [ Time Frame: From enrollment until disease progression or unacceptable toxicity, assessed up to 48 months ]
    Objective Response Rate (ORR) defined as the percentage of patients enrolled in each study arm with a best response of Complete Response (CR) or Partial Response (PR) as determined by the blinded independent review committee (BIRC).

  2. Primary Outcome [ Time Frame: From date of randomization to the earliest date of documented progressive disease (PD), assessed up to 48 months ]
    Progression-free Survival (PFS) defined as the time from the date of randomization to the first date of documented disease progression.


Secondary Outcome Measures :
  1. Secondary Outcome [ Time Frame: From date of randomization to death due to any cause, assessed up to 48 months ]
    Overall Survival (OS) defined as the time from date of randomization to the date of death due to any cause.

  2. Secondary Outcome [ Time Frame: From date of randomization until the end of study, assessed up to 48 months ]
    Safety defined as incidence of adverse events (AEs), severity (CTCAE v.5.0), causal relationship assessment, and outcomes of reported AEs.


Other Outcome Measures:
  1. Other Outcome Measures [ Time Frame: From first date of PR or better to the first date of PD, assessed up to 48 months ]
    Duration of Response (DoR) defined as the time from the first date of PR or better as determined by the BIRC to the first date of Progressive Disease (PD).

  2. Other Outcome Measures [ Time Frame: Assessed up to 48 months ]
    Disease Control Rate (DCR) defined as the proportion of total patients enrolled in each study arm with best response of CR, PR or stable disease (SD) of at least 12 weeks as determined by BIRC, compared between test and control arms.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histopathologically confirmed diagnosis of non-uveal, Stage III (unresectable), or Stage IV (metastatic) melanoma according to AJCC staging system (8th edition)
  2. Known BRAF V600 mutation status or consent to BRAF V600 mutation testing before randomization.
  3. Tumor tissue available for PD-L1 testing at central lab. PD-L1 expression level is required for randomization. In order to be randomized, a patient must be classified as PD-L1 positive or PD-L1 negative according to the following criteria:

    • PD-L1 positive (≥ 5% tumor cell membrane staining in a minimum of a hundred evaluable tumor cells) vs
    • PD-L1 negative (< 5% tumor cell membrane staining in a minimum of a hundred evaluable tumor cells).

    Note: If an insufficient amount of tumor tissue from an unresectable or metastatic site is available prior to the start of the Screening Phase, patients must consent to allow the acquisition of additional tumor tissue for assessment of the biomarker.

  4. Males or females 12 years of age or older.
  5. ECOG performance status ≤1 for age ≥18 years, Lansky performance score ≥80% for age 12 to 17 years.
  6. At least one measurable lesion defined by RECIST 1.1 criteria, (separate from the lesion to be used for tumor tissue collection for PD-L1 testing) not counting brain metastasis with:

    • Longest diameter ≥10 mm by CT (when slice thickness is ≤5 mm); or ≥ 2× slice thickness (when slice thickness is >5 mm)
    • Pathologically enlarged lymph node: ≥15 mm in short axis by CT (when slice thickness is ≤5 mm)
    • Clinical: ≥10 mm (that can be accurately measured with calipers)
  7. Have not received anti-PD-1, anti-PD-L1 or other systemic therapy for unresectable or metastatic melanoma, except for the following, provided that the patient has recovered from all treatment-related toxicities:

    1. BRAF mutation targeting therapy > 4 weeks before administration of Study Treatment.
    2. Adjuvant or neoadjuvant therapy with PD-1 or PD-L1 inhibitors or anti-CTLA-4) is allowed if disease progression/or recurrence occurred at least 6 months after the last dose and no clinically significant immune related toxicities leading to treatment discontinuation were observed
    3. Adjuvant interferon therapy must have been completed > 6 weeks before administration of Study Treatment
  8. Any prior radiotherapy or minor surgery must be completed at least 2 weeks and 1 week respectively before Day 1 dosing and recovered from all treatment related toxicities
  9. Screening laboratory results within 14 days prior to randomization:

    1. Hematology: WBC ≥3000/μL, neutrophils ≥1500/μL, platelets ≥100 × 103/μL, hemoglobin ≥10.0 g/dL independent of transfusion. The use of erythropoietic growth factor to achieve hemoglobin (Hgb) ≥ 10 g/dl is acceptable.
    2. The CrCL≥ 30 mL/min using Cockcroft-Gault formula.
    3. AST and ALT ≤3 × ULN, alkaline phosphatase ≤2.5 × ULN unless bone metastases present (patients with documented bone metastases: alkaline phosphatase <5 x ULN), bilirubin ≤ 1.5 × ULN (unless known Gilbert's disease where it must be ≤ 3 × ULN), serum albumin ≥ 3.0 g/dL).
  10. Negative serum pregnancy test at baseline for women of childbearing potential.
  11. Females of childbearing potential (non-surgically sterile or premenopausal female capable of becoming pregnant) and all males (due to potential risk of drug exposure through the ejaculate) must agree to use adequate birth control measures from study start, during the study and for 5 months after the last dose of Study Drug. Acceptable methods of birth control in this trial include two highly effective methods of birth control (as determined by the Investigator; one of the methods must be a barrier technique) or abstinence.
  12. Have the ability to understand and the willingness to sign a written informed consent document, comply with study scheduled treatment, visits and assessments.

Exclusion Criteria:

  1. History of ≥ Grade 3 hypersensitivity reactions to monoclonal antibodies.
  2. Previous treatment with a PD-1, PD-L1, PD-L2, CTLA-4 inhibitor, or any other agents targeting T-cell co-stimulation or immune checkpoint pathways for unresectable or metastatic melanoma.
  3. History of a cardiovascular illness including: congestive heart failure (New York Heart Association Grade III or IV); unstable angina or myocardial infarction within the previous 6 months; or symptomatic cardiac arrhythmia despite medical management. QT interval corrected by heart rate using QTcF >450 ms in males or >470 ms in females, or congenital long QT syndrome.
  4. Uncontrolled hypertension, systolic blood pressure (SBP) >160 mmHg or diastolic blood pressure (DBP) >100 mmHg.
  5. Patients with new, active, or progressive brain metastases or leptomeningeal disease with except when considered for a separate stratum for "Inclusion of Patients with Progressive Brain Metastasis"
  6. History of hemorrhagic diarrhea, inflammatory bowel disease, active uncontrolled peptic ulcer, or bowel resection that affects absorption of orally administered drugs.
  7. Active, known, or suspected autoimmune disease, except for Type I diabetes mellitus, hypothyroidism requiring only hormone replacement, or skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic therapy.
  8. Active uncontrolled bacterial, viral, or fungal infection requiring systemic therapy.
  9. Known history of testing positive for HIV, known AIDS.
  10. Hepatitis B surface antigen positive or hepatitis C antibody positive. Further investigation per institutional practices may be performed to exclude active infection.
  11. Patients with a condition requiring chronic systemic treatment with either corticosteroids (>10 mg daily prednisone or equivalents) or other immunosuppressive medications within 14 days before administration of Study Treatment. Inhaled or topical steroids, or adrenal replacement dose of corticosteroids at dose ≤ 10 mg/day prednisone equivalent are permitted.
  12. Use of another investigational agent (drug or vaccine not marketed for any indication) 28 days or before administration of Study Treatment. If the investigational agent is a monoclonal antibody then within 3 months before administration of Study Treatment
  13. Pregnant or breast-feeding women.
  14. Second malignancy unless in remission for 2 years or locally curable cancers that have been treated with curative intent with no evidence of recurrence, such as:

    • Basal or squamous cell skin cancer
    • Superficial bladder cancer
    • Carcinoma in situ of cervix or breast
    • Incidental prostate cancer
    • Non melanomatous skin cancer
    • Carcinoma in situ of the cervix treated with curative intent
    • Prostate cancer treated with curative intent with serum prostate specific antigen (PSA) < 2.0 ng/mL
  15. Patients with medical conditions requiring administration of strong cytochrome P450 (CYP), CYP3A4 Inducers and Inhibitors..
  16. Uncontrolled adrenal insufficiency or active chronic liver disease.
  17. Has received approved live vaccine/live attenuated vaccines within 30 days of planned Cycle 1 Day 1. Inactivated viral vaccines are allowed; however intranasal influenza vaccines (e.g. Flu-Mist) are not allowed.
  18. Underlying medical conditions that, in the Investigator's opinion, will make the administration of Study Treatment hazardous or obscure the interpretation of toxicity determination or AEs.
  19. Unwilling or unable to comply with procedures required in this protocol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04674683


Contacts
Layout table for location contacts
Contact: Brenda Taylor (858) 798-8894 btaylor@huyabio.com

Locations
Layout table for location information
Australia, Queensland
University of the Sunshine Coast Recruiting
Buderim, Queensland, Australia, 4556
Contact: Susan Poechhacker    61 7 5456 5515    spoechha@usc.edu.au   
Principal Investigator: Hong Shue, M.D.         
Icon Cancer Centre Wesley Recruiting
South Brisbane, Queensland, Australia
Contact: Agnieszka Malczewski, M.D.    0408206624    Agnieszka.malczewski@icon.team   
Principal Investigator: Agnieszka Malczewski, M.D.         
Sponsors and Collaborators
HUYA Bioscience International
Investigators
Layout table for investigator information
Principal Investigator: Agnieszka Malczewski, MD,PhD,FAIC Icon Cancer Center
Principal Investigator: Hong Shue, MD, PhD University of the Sunshine Coast
Layout table for additonal information
Responsible Party: HUYA Bioscience International
ClinicalTrials.gov Identifier: NCT04674683    
Other Study ID Numbers: HBI-8000-303
First Posted: December 19, 2020    Key Record Dates
Last Update Posted: January 12, 2021
Last Verified: January 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by HUYA Bioscience International:
HBI-8000
nivolumab
melanoma
brain metastasis
Additional relevant MeSH terms:
Layout table for MeSH terms
Melanoma
Neoplasm Metastasis
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas
Neoplastic Processes
Pathologic Processes
Nivolumab
Antineoplastic Agents, Immunological
Antineoplastic Agents